Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
19 Novembre 2008 - 2:00PM
PR Newswire (US)
ALLEGAN, Mich., Nov. 19 /PRNewswire-FirstCall/ -- Perrigo Company
(NASDAQ:PRGO)(TASE:PRGO) today acknowledges the settlement of
patent litigation brought by Sanofi-Aventis (NYSE:SNY) against Barr
Laboratories, Inc. a subsidiary of Barr Pharmaceuticals, Inc.
(NYSE:BRL). The suit was brought in the U.S. District Court of
Delaware 2006 based upon Barr's filing of an ANDA for Triamcinolone
Acetonide Nasal Spray containing a paragraph IV certification. Barr
believes that it is the first to file an Abbreviated New Drug
Application (ANDA) containing a paragraph IV certification for
NASACORT AQ. Barr developed its Triamcinolone Acetonide Nasal Spray
product with Perrigo Company and the ANDA is awaiting final
approval from FDA. Under the terms of the settlement, Barr will be
able to market the ANDA product under license from Sanofi-Aventis
as early as June 15, 2011 if Barr's ANDA is approved by that date,
or earlier in certain circumstances. In addition, even if Barr's
ANDA is not approved, Barr will have a license to launch a generic
version of NASACORT AQ, supplied by Sanofi-Aventis, on December 1,
2013, or earlier, in certain circumstances. Upon product launch,
Barr would pay Sanofi-Aventis a royalty. Perrigo will share in the
costs and benefits of the settlement agreement between Barr and
Sanofi-Aventis and in Barr's marketing of the products under the
agreement. NASACORT AQ (Triamcinolone Acetonide) Nasal Spray is
indicated for the treatment of the nasal symptoms of seasonal and
perennial allergic rhinitis in adults and children 6 years of age
and older. NASACORT AQ had annual sales of approximately $336
million for the twelve months ended September 2008, based on
Wolters Kluwer Health sales data. Perrigo Company is a leading
global healthcare supplier that develops, manufactures and
distributes OTC and prescription pharmaceuticals, nutritional
products, active pharmaceutical ingredients (API) and consumer
products. The Company is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. The Company's
primary markets and locations of manufacturing facilities are the
United States, Israel, Mexico and the United Kingdom. Visit Perrigo
on the Internet ( http://www.perrigo.com/ ). Note: Certain
statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and are subject to the safe harbor created
thereby. These statements relate to future events or the Company's
future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
levels of activity, performance or achievements of the Company or
its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases,
forward-looking statements can be identified by terminology such as
"may," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict,"
"potential" or other comparable terminology. The Company has based
these forward-looking statements on its current expectations,
assumptions, estimates and projections. While the Company believes
these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions
and involve known and unknown risks and uncertainties, many of
which are beyond the Company's control. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-K for the year ended June 28, 2008, as well as
the Company's subsequent filings with the Securities and Exchange
Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless
otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Perrigo Company CONTACT:
Arthur J. Shannon, Vice President, Investor Relations and
Communication of Perrigo Company, +1-269-686-1709, Web site:
http://www.perrigo.com/
Copyright
Barr (NYSE:BRL)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Barr (NYSE:BRL)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024